Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS in newly diagnosed TNBC
NCT02276443Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2015
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Open-label trial in triple-negative breast cancer (TNBC) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Response rate at 5 years. Started Nov 2015; status: active, not recruiting.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02276443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02276443.